Clinical Trial Update: First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating first-line gemcitabine, cisplatin, and MEK162 in advanced biliary tract carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Biliary Tract Cancer
• Biliary Tract Carcinoma
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• MEK162 (binimetinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Biliary Tract Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-11-17